NCT06528691 2026-02-17
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
St. Jude Children's Research Hospital
Phase 2 Recruiting
Clinical Trials
18 trialsNCT06964737 2025-10-29
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT03018288 2025-08-08
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02507583 2025-05-07
Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
Thomas Jefferson University
Phase 1 Completed
NCT02794883 2022-04-18
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
Northwestern University
Phase 2 Completed
NCT01567202 2020-09-09
Study of DC Vaccination Against Glioblastoma
Huashan Hospital
Phase 2 Unknown
NCT01644955 2018-07-02
Carboplatin in Treating Patients With Recurrent High-Grade Gliomas
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01213407 2016-05-19
GBM-Vax
Activartis Biotech
Phase 2 Completed
NCT00003484 2015-04-23
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
Duke University
Phase 1 Completed
NCT00024570 2014-11-14
Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
INSYS Therapeutics Inc
Phase 1/2 Completed
NCT00003461 2014-08-21
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
Duke University
Phase 1/2 Completed
NCT00003876 2013-06-26
Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003467 2013-06-20
Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma
Duke University
Phase 2 Completed
NCT00430079 2013-01-16
Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma
National Cancer Institute (NCI)
Phase NA Terminated
NCT00089427 2011-07-04
IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
INSYS Therapeutics Inc
Phase 1 Completed
NCT00024557 2011-06-06
Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
INSYS Therapeutics Inc
Phase 1 Completed
NCT00041587 2011-06-06
Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
INSYS Therapeutics Inc
Phase 1/2 Completed
NCT00076986 2011-06-06
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
INSYS Therapeutics Inc
Phase 3 Completed